3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 1/2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
13
Lymphoma, Follicular
3
Waldenstrom Macroglobulinemia
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia
2
Lymphoma, B-Cell
1
Lymphoma
1
Hematologic Diseases
1
Interventions
Rituximab
23
Cyclophosphamide
11
Radiotherapy
8
Prednisone
8
Vincristine
7
Doxorubicin
7
Lenalidomide
6
Bendamustine Hydrochloride
5
Chlorambucil
4
Peripheral Blood Stem Cell Transplantation
3
Filgrastim
3
obinutuzumab
2
liposomal amphotericin B
2
idelalisib
2
ibrutinib
2
fludarabine phosphate
2
VAP-cyclo protocol
2
Therapeutics
2
Psychiatric Rehabilitation
2
Levofloxacin
2
Interferon-alpha
2
Idarubicin
2
Epoetin Alfa
2
Early Intervention, Educational
2
Cyclosporine
2
Busulfan
2
zanubrutinib
1
tafasitamab
1
parsaclisib
1
orelabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell, Marginal Zone
×
idelalisib
×
Clear all
NCT01732913
2018-11-16
Yosemite
Gilead Sciences
Phase 3
Terminated
295 enrolled
9 charts
NCT01732926
2018-11-16
Bridalveil
Gilead Sciences
Phase 3
Terminated
475 enrolled
9 charts